Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 3 2Phase 1 1

Status

Completed 7Unknown 1Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1

Conditions

Pancreatic Neoplasms 1Lung Neoplasms 1Esophageal Neoplasms 1

Interventions

Cyclophosphamide 98pembrolizumab 87Gemcitabine 81Carboplatin 63fludarabine 62Nivolumab 57Cisplatin 54Paclitaxel 51Radiotherapy 50Docetaxel 50Rituximab 46Dexamethasone 42Lenalidomide 41Ipilimumab 38Azacitidine 35Etoposide 34Cytarabine 34Temozolomide 32Bevacizumab 32Radiation 29venetoclax 28Bortezomib 27Magnetic Resonance Spectroscopy 26Irinotecan 26atezolizumab 25Pemetrexed 25Oxaliplatin 24Capecitabine 24fludarabine phosphate 23Filgrastim 23

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Terminated × motesanib diphosphate × Clear all
NCT00101907 2014-03-20

Safety of AMG 706 Plus Panitumumab Plus Gemcitabine-Cisplatin in the Treatment of Patients With Advanced Cancer

Amgen

Phase 1 Terminated
41 enrolled 17 charts
GastrointestinalThoracic

Esophageal Neoplasms, Lung Neoplasms, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡